Issue 3/2019
Content (26 Articles)
Clinical implications of germline mutations in breast cancer genes: RECQL
A. Ramsay Bowden, Marc Tischkowitz
National consensus recommendations on patient-centered care for ductal carcinoma in situ
Anna R. Gagliardi, Frances C. Wright, Nicole J. Look Hong, Gary Groot, Lucy Helyer, Pamela Meiers, May Lynn Quan, Robin Urquhart, Rebecca Warburton
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
Elisabeth Specht Stovgaard, Anne Dyhl-Polk, Anne Roslind, Eva Balslev, Dorte Nielsen
Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis
Seyed-Mehdi Hashemi, Abbas Balouchi, Adhra Al-Mawali, Hosein Rafiemanesh, Khadije Rezaie-Keikhaie, Salehoddin Bouya, Behroz Dehghan, Mansoureh Ashghali Farahani
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
Fausto Petrelli, Antonio Ghidini, Rebecca Pedersini, Mary Cabiddu, Karen Borgonovo, Maria Chiara Parati, Mara Ghilardi, Vito Amoroso, Alfredo Berruti, Sandro Barni
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types
Patrick H. Dinkelborg, Meng Wang, Liliana Gheorghiu, Joseph M. Gurski, Theodore S. Hong, Cyril H. Benes, Dejan Juric, Rachel B. Jimenez, Kerstin Borgmann, Henning Willers
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
Takuro Yamamoto, Noriko Kanaya, George Somlo, Shiuan Chen
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC
Seiichi Imanishi, Yasuto Naoi, Kenzo Shimazu, Masafumi Shimoda, Naofumi Kagara, Tomonori Tanei, Tomohiro Miyake, Seung Jin Kim, Shinzaburo Noguchi
Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients
Ziguo Yang, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Juan Zhang, Yuntao Xie
Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior
C. D. Savci-Heijink, H. Halfwerk, G. K. J. Hooijer, J. Koster, H. M. Horlings, S. L. Meijer, M. J. van de Vijver
Expression of Lamin A/C in early-stage breast cancer and its prognostic value
I. M. Alhudiri, C. C. Nolan, I. O. Ellis, A. Elzagheid, E. A. Rakha, Andrew R. Green, C. J. Chapman
Three-dimensional tumor visualization of invasive breast carcinomas using whole-mount serial section histopathology: implications for tumor size assessment
G. M. Clarke, C. M. B. Holloway, J. T. Zubovits, S. Nofech-Mozes, M. Murray, K. Liu, D. Wang, A. Kiss, M. J. Yaffe
Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis
Ramy Gadalla, Hebatallah Hassan, Sherif Abdelaziz Ibrahim, Mahmoud Salah Abdullah, Ahmed Gaballah, Burkhard Greve, Somaya El-Deeb, Mohamed El-Shinawi, Mona Mostafa Mohamed
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Alberto Ocana, Marta Gil-Martin, Silvia Antolín, María Atienza, Álvaro Montaño, Nuria Ribelles, Ander Urruticoechea, Alejandro Falcón, Sonia Pernas, Javier Orlando, Juan Carlos Montero, Maria José Escudero, Sara Benito, Rosalía Caballero, Eva Carrasco, Federico Rojo, Atanasio Pandiella, Manuel Ruiz-Borrego
Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography
Daniel Ben Lustig, Rebecca Warburton, Carol K. Dingee, Urve Kuusk, Jin-Si Pao, Elaine C. McKevitt
Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
Marissa L. G. Vane, Maria A. Willemsen, Lori M. van Roozendaal, Sander M. J. van Kuijk, Loes F. S. Kooreman, Sabine Siesling, Hans H. W. de Wilt, Marjolein L. Smidt
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo, R. S. Finn, V. Diéras, J. Ettl, O. Lipatov, A. A. Joy, N. Harbeck, A. Castrellon, S. Iyer, D. R. Lu, A. Mori, E. R. Gauthier, C. Huang Bartlett, K. A. Gelmon, D. J. Slamon
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, Arshi Denton, Simon Waters, Ailsa Sita-Lumsden, Farah Rehman, Chara Stavraka, Hartmut Kristeleit, Elinor Sawyer, David Houghton, Neville Davidson, Sacha Howell, Julia Choy, Peter Harper, Rebecca Roylance, Raja Fharat, Kabir Mohammed, Alistair Ring, Stephen Johnston
Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case–control study
Shana J. Kim, Cindy X. W. Zhang, Rochelle Demsky, Susan Armel, Young-In Kim, Steven A. Narod, Joanne Kotsopoulos
Pre-diagnostic sex hormone levels and survival among breast cancer patients
Kevin H. Kensler, A. Heather Eliassen, Bernard A. Rosner, Susan E. Hankinson, Myles Brown, Rulla M. Tamimi
Comparison of treatment of early-stage breast cancer among Nurses’ Health Study participants and other Medicare beneficiaries
Andrea M. Austin, Nirav S. Kapadia, Gabriel A. Brooks, Tracy L. Onega, A. Heather Eliassen, Rulla M. Tamimi, Michelle Holmes, Qianfei Wang, Francine Grodstein, Anna N. A. Tosteson
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
Jan Lubinski, Tomasz Huzarski, Jacek Gronwald, Cezary Cybulski, Tadeusz Debniak, Ping Sun, Shana J. Kim, Joanne Kotsopoulos, Steven A. Narod
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Alex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, Aurélie Ayme, Solène De Talhouet, Jean-Damien Combes, Julien Peron, Alexandre Bodmer, Sophie Giraud, Adrien Buisson, Valerie Bonadona, Isabelle Gauchat-Bouchardy, Olivier Tredan, Pierre O. Chappuis, S. Intidhar Labidi-Galy
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
Xiaoqing Xu, Rowan T. Chlebowski, Jiaxiao Shi, Ana Barac, Reina Haque
Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
Stephanie Robertson, Caroline Rönnlund, Jana de Boniface, Johan Hartman